<DOC>
	<DOCNO>NCT00698763</DOCNO>
	<brief_summary>The primary objective explore safety low dose oral levosimendan patient recent history ischaemic cerebrovascular event ( stroke TIA ) . The main focus evaluation proarrhythmic potential different dose regimen .</brief_summary>
	<brief_title>Effects Oral Levosimendan Ambulatory Electrocardiographic Variables</brief_title>
	<detailed_description>This prospective , multicentre , phase II , randomize , double-blind , placebo-controlled 2-arm parallel group study 5 escalate dose-levels oral levosimendan , give 13-18 day . The study population randomly allocate either levosimendan group placebo group . The double-blind phase either placebo levosimendan precede 13-day long single-blind treatment placebo ( placebo run-in ) . The study consist 9 visit ( screen visit , 7 visit treatment period end-of-study visit ) . Each subject study treatment ( include placebo run-in ) 78-108 day duration study subject , include screen end study visit , approximately 17 week .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>Male female patient 50 80 year age ischaemic stroke TIA within 1 9 month screen visit . Stroke TIA due cardiac embolism , vasculitis arterial dissection Severe hemiparesis dysphasia , haemodynamically significant uncorrected valve disease hypertrophic cardiomyopathy restrictive cardiomyopathy , acute coronary event angioplasty major surgery within 1 month , major surgery plan study period History lifethreatening ventricular arrhythmia within 3 month . History Torsades de Pointes ( TdP ) family history long QTsyndrome Heart rate ( HR ) &lt; 50 &gt; 100 bpm . Systolic blood pressure ( SBP ) &lt; 100 mmHg &gt; 180 mmHg , diastolic blood pressure ( DBP ) &gt; 100 mmHg . Ventricular tachycardia . Episode atrial fibrillation atrial flutter last &gt; 60 second . Second third degree atrioventricular ( AV ) block . Potassium ( K ) &lt; 3.7 mmol/l &gt; 5.5 mmol/l . Creatinine &gt; 170 Âµmol/l dialysis . Blood haemoglobin &lt; 10 g/dl ; clinically significant hepatic impairment .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>An ischaemic cerebrovascular event ( stroke TIA )</keyword>
</DOC>